scholarly journals Determinants of 20-year non-progression to Type 2 diabetes in women at very high risk: the E3N cohort study

2018 ◽  
Vol 35 (12) ◽  
pp. 1716-1721 ◽  
Author(s):  
G. Fagherazzi ◽  
G. Gusto ◽  
F. R. Mancini ◽  
C. Dow ◽  
K. Rajaobelina ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Cohort Study ◽  
High Risk ◽  
Very High

scholarly journals Clinical profiles and quality of care of subjects with type 2 diabetes according to their cardiovascular risk: an observational, retrospective study

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Basilio Pintaudi ◽  
Alessia Scatena ◽  
Gabriella Piscitelli ◽  
Vera Frison ◽  
Salvatore Corrao ◽  
...  
Keyword(s):  
Risk Factors ◽  
Type 2 Diabetes ◽  
Quality Of Care ◽  
Cardiovascular Risk ◽  
High Risk ◽  
Cardiovascular Risk Factors ◽  
High Cardiovascular Risk ◽  
Very High

Abstract Background The European Society of Cardiology (ESC) recently defined cardiovascular risk classes for subjects with diabetes. Aim of this study was to explore the distribution of subjects with type 2 diabetes (T2D) by cardiovascular risk groups according to the ESC classification and to describe the quality indicators of care, with particular regard to cardiovascular risk factors. Methods The study is based on data extracted from electronic medical records of patients treated at the 258 Italian diabetes centers participating in the AMD Annals initiative. Patients with T2D were stratified by cardiovascular risk. General descriptive indicators, measures of intermediate outcomes, intensity/appropriateness of pharmacological treatment for diabetes and cardiovascular risk factors, presence of other complications and overall quality of care were evaluated. Results Overall, 473,740 subjects with type 2 diabetes (78.5% at very high cardiovascular risk, 20.9% at high risk and 0.6% at moderate risk) were evaluated. Among people with T2D at very high risk: 26.4% had retinopathy, 39.5% had albuminuria, 18.7% had a previous major cardiovascular event, 39.0% had organ damage, 89.1% had three or more risk factors. The use of DPP4-i markedly increased as cardiovascular risk increased. The prescription of secretagogues also increased and that of GLP1-RAs tended to increase. The use of SGLT2-i was still limited, and only slightly higher in subjects with very high cardiovascular risk. The overall quality of care, as summarized by the Q score, tended to be lower as the level of cardiovascular risk increased. Conclusions A large proportion of subjects with T2D is at high or very high risk. Glucose-lowering drug therapies seem not to be adequately used with respect to their potential advantages in terms of cardiovascular risk reduction. Several actions are necessary to improve the quality of care.

Impact of ethnicity and obesity on insulin resistance in two ethnic groups at very high risk of type 2 diabetes

2017 ◽  
Vol 43 (3) ◽  
pp. 292-294 ◽  
Author(s):  
S. Hassoun ◽  
M. Al-Atrash ◽  
M. Alkasim ◽  
Z. Dabbous ◽  
O. Mujahed ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
High Risk ◽  
Ethnic Groups ◽  
Very High

Comorbidities and Diabetes Type 2

2021 ◽  
pp. 46-61
Author(s):  
Chinedu I. Ossai ◽  
Nilmini Wickramasinghe ◽  
Steven Goldberg
Keyword(s):  
Type 2 Diabetes ◽  
High Risk ◽  
Logit Model ◽  
Diabetes Type 2 ◽  
Cost Effective ◽  
Diabetes Type ◽  
High Quality ◽  
Chi Square ◽  
Very High

The prevalence of diabetes type 2 among the population and the increasing rate of new diagnoses as well as other co-morbidities make it imperative that we develop a richer understanding of type 2 diabetes. An Australian survey of diabetes type 2 people for different co-morbidities was carried out to obtain information about the possible connections of the co-morbidities with type 2 diabetes. The analysis is done with the logit model and Pearson's chi-square and the results indicate that gender, age of the patients, and the duration of the diabetes type 2 diagnosis play a significant role in the exposure of individuals to different comorbidities. The influence of the duration of diagnosis and age of the patients is limited in comparison to the gender, which has females at a very high risk of developing the studied co-morbidities compared to males. The findings can improve diabetes type 2 management to boost high quality, proactive, and cost-effective caregiving for the patients.

scholarly journals Psychological Distress and Incidence of Type 2 Diabetes in High-Risk and Low-Risk Populations: The Whitehall II Cohort Study

Diabetes Care ◽  
2014 ◽  
Vol 37 (8) ◽  
pp. 2091-2097 ◽  
Author(s):  
Marianna Virtanen ◽  
Jane E. Ferrie ◽  
Adam G. Tabak ◽  
Tasnime N. Akbaraly ◽  
Jussi Vahtera ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Cohort Study ◽  
Psychological Distress ◽  
High Risk ◽  
Low Risk

A simple risk score identifies individuals at high risk of developing Type 2 diabetes: a prospective cohort study

2008 ◽  
Vol 25 (3) ◽  
pp. 191-196 ◽  
Author(s):  
M. Rahman ◽  
R. K. Simmons ◽  
A.-H. Harding ◽  
N. J. Wareham ◽  
S. J. Griffin
Keyword(s):  
Type 2 Diabetes ◽  
Cohort Study ◽  
High Risk ◽  
Prospective Cohort Study ◽  
Risk Score ◽  
Prospective Cohort

scholarly journals Evaluation of the HbA1c Reduction Cut Point for a Nonglycemic Effect on Cardiovascular Benefit of Hypoglycemic Agents in Patients with Type 2 Diabetes Based on Endpoint Events

2018 ◽  
Vol 2018 ◽  
pp. 1-7 ◽  
Author(s):  
Yuchao Wu ◽  
Lizhi Tang ◽  
Fang Zhang ◽  
Zhe Yan ◽  
Jing Li ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Primary Prevention ◽  
High Risk ◽  
Secondary Prevention ◽  
Glucose Control ◽  
Hypoglycemic Agents ◽  
Intensive Glucose Control ◽  
Very High ◽  
Cardiovascular Benefit

Background. Atherosclerotic cardiovascular disease (ASCVD) is a major cause of death among patients with diabetes but can be improved by certain hypoglycemic agents. However, adjudicating criteria on whether improvements are a glycemic or nonglycemic effect of these agents remain unclear. Methods. Hypoglycemic agents that produce a cardiovascular benefit in nondiabetic patients are considered to do so via a nonglycemic effect. We performed a subgroup analysis for primary and secondary prevention or very high risk of ASCVD in patients with type 2 diabetes (T2DM). Where glycosylated hemoglobin (HbA1c) was reduced to the same extent in a head-to-head comparison, cardiovascular benefits were judged as a nonglycemic effect. Furthermore, by analyzing the endpoints of four important randomized controlled intensive glucose control studies, UKPDS33, ADVANCE, ACCORD, and VADT, we calculated the cut point of HbA1c reduction for a nonglycemic effect on cardiovascular benefit by hypoglycemic agents in ASCVD groups of different severities. Results. For the ASCVD primary prevention group of T2DM, UKPDS33 indicated a reduction in HbA1c < 0.9%, and a cardiovascular benefit within 10 years was considered a nonglycemic effect. For ASCVD secondary prevention or in the very high-risk group, pioglitazone exerted a nonglycemic effect on cardiovascular benefit in nondiabetic patients with insulin resistance; metformin may exert a similar effect in T2DM patients in a head-to-head study. Analysis of T2DM intensive glucose control studies showed a reduction in HbA1c of <1.0%, and a cardiovascular benefit after approximately 5 years was deemed a nonglycemic effect. Conclusions. For ASCVD primary prevention in T2DM, a reduction in HbA1c < 0.9% and a cardiovascular benefit within 10 years were considered a nonglycemic effect. For ASCVD secondary prevention or in a very high-risk population, a reduction in HbA1c < 1.0% and a cardiovascular benefit within about 5 years were also considered a nonglycemic effect.

scholarly journals Association of the KDIGO Risk Classification with the Prevalence of Heart Failure in Patients with Type 2 Diabetes

2021 ◽  
Vol 10 (20) ◽  
pp. 4634
Author(s):  
José Antonio Gimeno-Orna ◽  
Luis Rodríguez-Padial ◽  
Manuel Anguita-Sánchez ◽  
Vivencio Barrios ◽  
Javier Muñiz ◽  
...  
Keyword(s):  
Heart Failure ◽  
Type 2 Diabetes ◽  
High Risk ◽  
Sleep Apnoea ◽  
Risk Classification ◽  
Risk Category ◽  
Cross Sectional ◽  
Obstructive Sleep ◽  
Very High

The objectives of this study were to determine the main characteristics associated with the presence of heart failure (HF) in patients with type 2 diabetes (T2DM), and specifically to assess the association of the risk classification proposed by the Kidney Disease Improving Global Outcomes (KDIGO) guidelines with HF. The DIABET-IC study is a multicentre, observational, prospective and analytical study in T2DM patients recruited in Spanish hospitals. This work, which features a cross-sectional design, has been conducted with the data obtained at the inclusion visit. The main dependent variable analysed was the presence of HF. The predictive variables evaluated were the demography, clinic, laboratory testing (including natriuretic peptides) and echocardiography. Patients were classified according to the number of vascular territories with atherosclerotic involvement and the KDIGO risk category. Multivariate logistic regression models were performed to determine the risk posed by the various baseline variables to present HF at the time of study inclusion. The study included 1517 patients from 58 hospitals, with a mean age of 67.3 (standard deviation (SD): 10) years, out of which 33% were women. The mean DM duration was 14 (SD: 11) years. The prevalence of HF was 37%. In a multivariate analysis, the independent predictors of HF were increased age (odds ratio (OR) per 1 year = 1.02; p = 0.006), decreased systolic blood pressure (OR per 1 mmHg = 0.98; p <0.001), decreased haemoglobin (OR per 1 g/dL = 0.86; p <0.001), the presence of obstructive sleep apnoea (OR = 1.61; p = 0.006), the absence of hepatic steatosis (OR = 0.59; p = 0.016), the severity of atherosclerotic involvement (OR 1 territory = 1.38 and OR >1 territory = 2.39; p = 0.02 and p<0.001 respectively) and the KDIGO risk classification (high-risk OR = 2.46 and very high-risk OR = 3.39; p <0.001 for both). The KDIGO risk classification is useful to screen for the presence of HF in T2DM patients. Therefore, we believe that it is necessary to carry out a systematic screening for HF in the high- and very high-risk KDIGO categories.

scholarly journals Impact on the physical activity level of adults at high and very high risk of developing type 2 diabetes mellitus: email follow-up intervention

2019 ◽  
Vol 25 (4) ◽  
Author(s):  
Carla Giuliano de Sá Pinto Montenegro ◽  
Rafael Mathias Pitta ◽  
Marcio Marega ◽  
Roberta L. Rica ◽  
Luis Felipe Tubagi Polito ◽  
...  
Keyword(s):  
Physical Activity ◽  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
High Risk ◽  
Physical Activity Level ◽  
Activity Level ◽  
Very High

Estudio Transversal: Riesgo Cardiovascular en Diabetes Mellitus II según Score UKPDS en pacientes del Hospital José Carrasco Arteaga

2020 ◽  
Vol 12 (3) ◽  
pp. 178-187
Author(s):  
Paola Cristina Bacuilima Zhañay ◽  
Andrea Catalina Ochoa Bravo
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cardiovascular Risk ◽  
High Risk ◽  
Glycemic Control ◽  
Diabetic Patients ◽  
Clinical Records ◽  
Very High

BACKGROUND: Type 2 Diabetes Mellitus (DM2) is a disease of great health and socioeconomic impact. Cardiovascular complications are the main cause of death in diabetic patients, for this reason the application of prevention strategies is important. The aim of the research was to determine the cardiovascular risk according to UKPDS Score in patients diagnosed with DM2, treated at Hospital José Carrasco Arteaga, Cuenca-Ecuador, from November 2918 to August 2019. METHODS:A descriptive, cross-sectional study was conducted with a sample of 118 patients diagnosed with DM2, treated at Hospital José Carrasco Arteaga, between November 2018 and August 2019. Clinical records were reviewed, information was collected on a form with all the variables of the UKPDS Score. Cardiovascular Risk Estimation (RCV) was carried out with the Risk Engine Calculator version 2.0 of the UKPDS Score. RESULTS: The female sex predominated in the study population. The age range went from 32 to 95 years old, the most frequent range of age was 55 to 59 years old (16.1%). The disease duration in 40% of the population was higher than 10 years. 42.4 %(n=50) presented SBP values ≥130mmHg. 75.4% of the sample had poor glycemic control, with glycosylated hemog-lobin levels higher than the normal range for each age group. The estimated 5-year CVR was low for most of the sample; while the 10 year CVR increased, especially for non-fatal CVD(high risk:21.25%) and for fatal (6.8%) and non-fatal(6.8%) AMI. CONCLUSION:Most of the patients had more than 10 years with DMII diagnosis. More than half of the sample had inadequate glycemic control. The CVR at 5 years was “low” for the majority of the population, both for AMI and CVD. The cardiovascular risk at 10 years was slightly higher for all entities, especially it increases for non-fatal CVD, to a “very high risk” of 21.2%, and the risk of AMI also increases to a “very high risk” of 6.8%. KEYWORDS: TYPE 2 DIABETES MELLITUS, CARDIOVASCULAR DISEASES, MYOCARDIAL INFARCTION, CEREBROVASCULAR STROKE

Sign in / Sign up

Export Citation Format

Share Document